For World NET Cancer Day, CURE answers seven common questions about neuroendocrine tumors, from carcinoid syndrome and Ki-67 to dotatate PET scans and treatment options.
|Articles|April 15, 2016
- Gastrointestinal Special Issue
- Volume 1
- Issue 1
Medical Illustration: Targeting HER2 in Gastric Cancer
Author(s)Erin Moore
For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.
Advertisement
ILLUSTRATION BY ERIN MOORE
ORIGINALLY PUBLISHED IN “GUT REACTION,” CURE WINTER 2009
*HER2 is also associated with breast cancer.
For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.
Articles in this issue
over 10 years ago
In Gastroesophageal Cancers, Better Prevention and Treatments Neededover 10 years ago
An Insight Into Gastric Cancers and Life Without a Stomachover 10 years ago
Changing Lives With ImmunotherapyAdvertisement
Related to this article
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
2
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
3
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
4
Inside the Clinic: How One Hematologist Approaches a Rare Leukemia
5